1.Molecular deconvolution of the neutralizing antibodies induced by an inactivated SARS-CoV-2 virus vaccine.
Xingdong ZHOU ; Hui WANG ; Qun JI ; Mingjuan DU ; Yuexia LIANG ; Huanhuan LI ; Fan LI ; Hang SHANG ; Xiujuan ZHU ; Wei WANG ; Lichun JIANG ; Alexey V STEPANOV ; Tianyu MA ; Nanxin GONG ; Xiaodong JIA ; Alexander G GABIBOV ; Zhiyong LOU ; Yinying LU ; Yu GUO ; Hongkai ZHANG ; Xiaoming YANG
Protein & Cell 2021;12(10):818-823
2.Weak SARS-CoV-2-specific responses of TIGIT-expressing CD8 + T cells in people living with HIV after a third dose of a SARS-CoV-2 inactivated vaccine.
Junyan JIN ; Xiuwen WANG ; Yongzheng LI ; Xiaodong YANG ; Hu WANG ; Xiaoxu HAN ; Jin SUN ; Zhenglai MA ; Junyi DUAN ; Guanghui ZHANG ; Tao HUANG ; Tong ZHANG ; Hao WU ; Xin ZHANG ; Bin SU
Chinese Medical Journal 2023;136(24):2938-2947
BACKGROUND:
T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibition motif domains (TIGIT), an inhibitory receptor expressed on T cells, plays a dysfunctional role in antiviral infection and antitumor activity. However, it is unknown whether TIGIT expression on T cells influences the immunological effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inactivated vaccines.
METHODS:
Forty-five people living with HIV (PLWH) on antiretroviral therapy (ART) for more than two years and 31 healthy controls (HCs), all received a third dose of a SARS-CoV-2 inactivated vaccine, were enrolled in this study. The amounts, activation, proportion of cell subsets, and magnitude of the SARS-CoV-2-specific immune response of TIGIT + CD4 + and TIGIT + CD8 + T cells were investigated before the third dose but 6 months after the second vaccine dose (0W), 4 weeks (4W) and 12 weeks (12W) after the third dose.
RESULTS:
Compared to that in HCs, the frequency of TIGIT + CD8 + T cells in the peripheral blood of PLWH increased at 12W after the third dose of the inactivated vaccine, and the immune activation of TIGIT + CD8 + T cells also increased. A decrease in the ratio of both T naïve (T N ) and central memory (T CM ) cells among TIGIT + CD8 + T cells and an increase in the ratio of the effector memory (T EM ) subpopulation were observed at 12W in PLWH. Interestingly, particularly at 12W, a higher proportion of TIGIT + CD8 + T cells expressing CD137 and CD69 simultaneously was observed in HCs than in PLWH based on the activation-induced marker assay. Compared with 0W, SARS-CoV-2-specific TIGIT + CD8 + T-cell responses in PLWH were not enhanced at 12W but were enhanced in HCs. Additionally, at all time points, the SARS-CoV-2-specific responses of TIGIT + CD8 + T cells in PLWH were significantly weaker than those of TIGIT - CD8 + T cells. However, in HCs, the difference in the SARS-CoV-2-specific responses induced between TIGIT + CD8 + T cells and TIGIT - CD8 + T cells was insignificant at 4W and 12W, except at 0W.
CONCLUSIONS
TIGIT expression on CD8 + T cells may hinder the T-cell immune response to a booster dose of an inactivated SARS-CoV-2 vaccine, suggesting weakened resistance to SARS-CoV-2 infection, especially in PLWH. Furthermore, TIGIT may be used as a potential target to increase the production of SARS-CoV-2-specific CD8 + T cells, thereby enhancing the effectiveness of vaccination.
Humans
;
Antibodies, Viral
;
CD8-Positive T-Lymphocytes
;
COVID-19/complications*
;
COVID-19 Vaccines/immunology*
;
HIV Infections/complications*
;
Receptors, Immunologic
;
SARS-CoV-2
3.Covid-19 vaccine management (Comirnaty and mrna-1273 Moderna) in a teaching hospital in Italy: a short report on the vaccination campaign.
Francesca PAPINI ; Niccolò GRASSI ; Giovanni GUGLIELMI ; Vittorio GATTINI ; Lucia RAGO ; Costanza BISORDI ; Monica SCATENI ; Michele TOTARO ; Alberto TULIPANI ; Andrea PORRETTA ; Lara TAVOSCHI ; Jacopo GUERCINI ; Grazia LUCHINI ; Silvia BRIANI ; Gaetano Pierpaolo PRIVITERA ; Angelo BAGGIANI
Environmental Health and Preventive Medicine 2021;26(1):99-99
OBJECTIVES:
In this article, we aim to share our experience in the hospital reorganization made to conduct the SARS-CoV-2 vaccination campaign, based on the principles of flexibility and adaptability.
STUDY DESIGN:
A descriptive study.
METHODS:
The data concerning the organization of the vaccination campaign were taken from the operative protocol developed by the hospital dedicated task force, composed by experts in hygiene, public health, occupational medicine, pharmacists, nurses, hospital quality, and disaster managers. Data about the numbers of vaccine administered daily were collected by the Innovation and Development Operative Unit database.
RESULTS:
Vaccinations against COVID-19 started across the EU on the 27th of December 2020. The first phase of the vaccination campaign carried out in our hospital was directed to healthcare workers immunization including medical residents, social care operators, administrative staff and technicians, students of medicine, and health professions trainees. The second phase was enlarged to the coverage of extremely fragile subjects. Thanks to the massive employment of healthcare workers and the establishment of dynamic pathways, it was possible to achieve short turnaround times and a large number of doses administered daily, with peaks of 870 vaccines per day. From the 27th of December up to the 14th of March a total of 26,341 doses of Pfizer have been administered. 13,584 were first doses and 12,757 were second doses. From the 4th to the 14th of March, 296 first doses of Moderna were dispensed. It was necessary to implement adequate spaces and areas adopting anti-contagion safety measures: waiting area for subjects to be vaccinated, working rooms for the dilution of the vaccine and the storage of the material, vaccination rooms, post-vaccination observation areas, room for observation, and treatment of any adverse reactions, with an emergency cart available in each working area.
CONCLUSIONS
The teaching hospital of Pisa faced the beginning of the immunization campaign readjusting its spaces, planning an adequate hospital vaccination area and providing an organization plan to ensure the achievement of the targets of the campaign. This represented a challenge due to limited vaccine doses supplied and the multisectoral teams of professionals to coordinate in the shortest time and the safest way possible. The organizational model adopted proved to be adequate and therefore exploited also for the second phase aimed to extremely fragile subjects.
2019-nCoV Vaccine mRNA-1273
;
BNT162 Vaccine
;
COVID-19/prevention & control*
;
COVID-19 Vaccines/administration & dosage*
;
Hospitals, Teaching/organization & administration*
;
Humans
;
Immunization Programs/organization & administration*
;
Italy/epidemiology*
;
SARS-CoV-2/immunology*